Howard Rutman

Dr. Rutman is the Group Vice President and Medical Director of Taro Pharmaceuticals, a multinational, science-driven specialty and generic pharmaceutical company. As Medical Director, he oversees the Phase II and Phase III clinical research program for several novel IND/NDA products and interacts with the FDA on the development and approval process. He also establishes contacts with the scientific and investor community on potential strategic alliances and business development opportunities. Dr. Rutman received his undergraduate education at Harvard, his medical degree from Johns Hopkins and his MBA from Stern-NYU.

He currently serves on the clinical cardiology teaching services of two university medical centers – the Albert Einstein College of Medicine and the Mount Sinai School of Medicine, continuing his 20-year experience of academic teaching and Park Avenue cardiology practice in New York City.